It is an Alpha-Bungarotoxin neuronal nicotinic receptor antagonist with selective nanomolar affinity for a subtype of neuronal nAChR in the brain that probably incorporates the Alpha7 subunit, compared with micromolar affinity at muscle nAChR and at Alpha-Bungarotoxin insensitive neuronal nAChR.

It is a medium-lasting myorelaxing activity. As a tertiary amine, Methyllycaconitine (MLA) crosses histohematic barriers and is active orally: blockage of Nicotinic cholinoreceptors of striated muscles at 2.5-3.5 mg/kg (i.v.) and 30-40 mg/kg (p.o.);
MLA relates to the non-depolarizing competitive myorelaxing agents, and its antagonists are Galanthamine and Neostigmine.
0.5-2 mg/kg (i.v.) has a hypotensive activity due to the inhibition of nervous influx transmission in sympathetic and parasympathetic ganglia. MLA acts directly on the brain and spinal cord.
It enhances the amplitude of monosynaptic potentials in inhibiting the Nicotinic receptors of Renshaw cells.
It removes totally the inhibiting effect of Nicotine on spinal cord monosynaptic responses.
In cats (i.v.), MLA has been shown to interact with brain Nicotinic receptors, eliminating variations of EEG caused by subecholine.
Recent studies show that MLA and some related diterpenoid alkaloids act as neuronal Alpha-Bungarotoxin sensitive brain nicotinic receptors antagonist.

Storage and reconstitution recommendations: Store at +4°C, in dark place.
Dissolves in water :
- at room temperature : up to 0.15 %
- at 40 °C : up to 0.3 %

For research use only — not intended for food, diagnostic or therapeutic use